Impact of NNRTI Resistance on RNase H & HIV Replication
NNRTI 耐药性对 RNase H 的影响
基本信息
- 批准号:6347109
- 负责人:
- 金额:$ 23.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-04-05 至 2002-03-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS therapy DNA footprinting RNA directed DNA polymerase active sites antiviral agents chemical cleavage clinical research drug resistance efavirenz gene mutation genetic polymorphism human immunodeficiency virus 1 human subject mutant reverse transcriptase inhibitors tissue /cell culture virus genetics virus replication
项目摘要
DESCRIPTION (provided by applicant): We are proposing to investigate the
effects of non-nucleoside inhibitor-resistance (NNRTI-R) mutations on HIV-1
replication and reverse transcriptase function. During the current funding
period, we have demonstrated that 4 NNRTI-R mutants of HIV-1 (K103N, V106A,
Y181C, and P236L) have characteristic effects on RNase H activity of HIV-1 RT.
We have also demonstrated that NNRTI-R mutants with greater reductions in RNase
H activity impair replication fitness in cell culture. Mutants that have
greater abnormalities in RNase H activity also appear to have a reduced
likelihood of appearing during clinical failure of NNRTIs. The RNase H cleavage
abnormalities that we have described affect not only non-specific RNase H
cleavages that degrade the viral RNA genome, but also the site-specific
cleavages that form the polypurine tract (PPT), which serves as the primer for
plus-strand synthesis. These findings are quite unexpected, since NNRTI-R
mutations are in the polymerase domain, remote from the RNase H active site.
Further study of these mutants should lead to a better understanding of (1) the
pathogenic consequences of selection for NNRTI-R mutants, (2) the effects of
RNase H cleavage on specific steps in reverse transcription and their
contribution to viral replication fitness, and (3) how RNase H cleavages are
modulated by residues in the polymerase domain of RT. We propose to pursue
these important questions with the following specific aims:
1. Determine the effects of NNRTI-R mutants on specific steps in reverse
transcription.
2. Determine the mechanisms by which NNRTI-R mutations affect RNase H cleavage.
3. Identify the mechanisms by which clinical isolates of HIV- 1 can compensate
for the reduced replication fitness conferred by NNRTI-R mutations.
4. Determine the factors that contribute to selection for secondary NNRTI-R
mutations during therapy with efavirenz.
In order to accomplish these specific aims, we will utilize a broad array of
experimental approaches, ranging from studies of RT structure and function in
vitro, to analyses of the replication characteristics and biochemical function
of HIV- 1 from patient samples.
描述(由申请人提供):我们建议调查
非核苷酸耐药(NNRTI-R)突变对HIV-1的影响
复制和逆转录酶功能。在目前的资金
在此期间,我们已经证明了HIV-1的4种NNRTI-R突变体(K103 N,V106 A,
Y181 C和P236 L)对HIV-1 RT的RNase H活性具有特征性影响。
我们还证明了RNase降低更大的NNRTI-R突变体,
H活性损害细胞培养中的复制适应性。突变体
RNA酶H活性的更大异常似乎也降低了
在NNRTI临床失败期间出现的可能性。RNase H切割
我们所描述的异常不仅影响非特异性RNase H,
裂解,降解病毒RNA基因组,但也位点特异性
裂解形成聚嘌呤段(PPT),它作为引物,
正链合成这些发现是相当出乎意料的,因为NNRTI-R
突变位于聚合酶结构域中,远离RNase H活性位点。
对这些突变体的进一步研究将导致更好地理解(1)
选择NNRTI-R突变体的致病性后果,(2)
RNA酶H在逆转录中特定步骤上的切割及其应用
对病毒复制适应性的贡献,以及(3)RNase H切割是如何
由RT的聚合酶结构域中的残基调节。我们建议追求
这些重要问题的具体目标如下:
1.确定NNRTI-R突变体对特定步骤的影响
转录。
2.确定NNRTI-R突变影响RNase H切割的机制。
3.确定HIV- 1临床分离株的补偿机制
因为NNRTI-R突变降低了复制适应性。
4.确定有助于选择二级NNRTI-R的因素
在依法韦仑治疗期间发生突变。
为了实现这些具体目标,我们将利用广泛的
实验方法,从RT结构和功能的研究,
体外培养,分析其复制特性和生化功能
HIV- 1病毒的样本。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lisa M. Demeter其他文献
Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring.
抗逆转录病毒药物药代动力学方面的最新进展:对治疗药物监测的影响。
- DOI:
- 发表时间:
2006 - 期刊:
- 影响因子:3.1
- 作者:
J. Slish;Linda M. Catanzaro;Qing Ma;O. Okusanya;Lisa M. Demeter;M. Albrecht;Gene D. Morse - 通讯作者:
Gene D. Morse
Lisa M. Demeter的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lisa M. Demeter', 18)}}的其他基金
Clinical Significance of HIV Replication Fitness
HIV 复制适应性的临床意义
- 批准号:
7369772 - 财政年份:2006
- 资助金额:
$ 23.93万 - 项目类别:
Clinical Significance of HIV Replication Fitness
HIV 复制适应性的临床意义
- 批准号:
7185102 - 财政年份:2006
- 资助金额:
$ 23.93万 - 项目类别:
Clinical Significance of HIV Replication Fitness
HIV 复制适应性的临床意义
- 批准号:
7064995 - 财政年份:2006
- 资助金额:
$ 23.93万 - 项目类别:
ACTG A5146: IMPACT OF THERAPEUTIC DRUG MONITORING IN SALVAGE REGIMENS
ACTG A5146:抢救方案中治疗药物监测的影响
- 批准号:
7200086 - 财政年份:2005
- 资助金额:
$ 23.93万 - 项目类别:
ACTG 317: TRIAL OF QUADRUPLE DRUG INDUCTION TREATMENT IN PT W/ ACUTE HIV INFECT
ACTG 317:急性 HIV 感染患者的四联药物诱导治疗试验
- 批准号:
7200060 - 财政年份:2005
- 资助金额:
$ 23.93万 - 项目类别:
DLV RESISTANCE MUTATIONS IN HIV REPLICATIONS
HIV 复制中的 DLV 抗性突变
- 批准号:
2887452 - 财政年份:1998
- 资助金额:
$ 23.93万 - 项目类别:
DLV RESISTANCE MUTATIONS IN HIV REPLICATIONS
HIV 复制中的 DLV 抗性突变
- 批准号:
6170442 - 财政年份:1998
- 资助金额:
$ 23.93万 - 项目类别:
相似海外基金
DNA footprinting of a plant defense gene family; to support visit by A.M. Yorkin, Department of Genetics, St. Petersburg State University, St. Petersburg, Russia
植物防御基因家族的 DNA 足迹;
- 批准号:
147394-1992 - 财政年份:1993
- 资助金额:
$ 23.93万 - 项目类别:
International: Foreign Researcher (H)